Get the Stockscreener App
5.87
0.00%
0.00
Solid Biosciences Inc stock is traded at $5.87, with a volume of 648.28K.
It is up +0.00% in the last 24 hours and up +23.84% over the past month.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
See More
Previous Close:
$5.87
Open:
$5.88
24h Volume:
648.28K
Relative Volume:
0.58
Market Cap:
$457.33M
Revenue:
$14.79M
Net Income/Loss:
$-102.44M
P/E Ratio:
-1.9309
EPS:
-3.04
Net Cash Flow:
$-91.73M
1W Performance:
+1.73%
1M Performance:
+23.84%
6M Performance:
+28.17%
1Y Performance:
+25.43%
1-Day Range:
$5.79
$6.04
1-Week Range:
$5.47
$6.04
52-Week Range:
$2.41
$7.37
Solid Biosciences Inc Stock (SLDB) Company Profile
Name
Solid Biosciences Inc
Sector
Industry
Phone
617-337-4680
Address
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
5.87 | 457.33M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-25 | Initiated | Needham | Buy |
| Jun-26-25 | Initiated | Citigroup | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-13-24 | Initiated | Wedbush | Outperform |
| Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-15-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | William Blair | Outperform |
| Mar-15-24 | Initiated | Citigroup | Buy |
| Mar-14-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | Piper Sandler | Neutral |
| May-27-21 | Initiated | Jefferies | Buy |
| Mar-16-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Jan-08-21 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jul-28-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-07-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-19 | Initiated | Evercore ISI | Outperform |
| Aug-29-19 | Downgrade | Citigroup | Neutral → Sell |
| Aug-19-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-16-19 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| May-14-19 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-14-19 | Downgrade | Goldman | Neutral → Sell |
| Feb-08-19 | Upgrade | Citigroup | Sell → Neutral |
| Feb-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-06-18 | Initiated | Citigroup | Sell |
| Sep-06-18 | Initiated | Credit Suisse | Neutral |
View All
Solid Biosciences Inc Stock (SLDB) Latest News
Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum - GlobeNewswire
Bollard Group LLC Acquires New Holdings in Solid Biosciences Inc. $SLDB - MarketBeat
Needham & Company LLC Upgrades Solid Biosciences (NASDAQ:SLDB) to Moderate Buy - MarketBeat
Geode Capital Management LLC Purchases 979,294 Shares of Solid Biosciences Inc. $SLDB - MarketBeat
Insider Selling: Solid Biosciences (NASDAQ:SLDB) CTO Sells 2,701 Shares of Stock - MarketBeat
Insider Selling: Solid Biosciences (NASDAQ:SLDB) COO Sells 4,932 Shares of Stock - MarketBeat
Solid Biosciences (NASDAQ:SLDB) CEO Sells 10,808 Shares - MarketBeat
Jessie Hanrahan Sells 4,483 Shares of Solid Biosciences (NASDAQ:SLDB) Stock - MarketBeat
Solid Biosciences CEO Cumbo sells $55k in shares By Investing.com - Investing.com Canada
Solid Biosciences CEO Cumbo sells $55k in shares - Investing.com India
Solid Biosciences Executives Sell Shares to Cover Taxes - TradingView — Track All Markets
Solid Biosciences: Better Positioned To Compete In DMD Gene Therapy, Says Bullish Analyst - Benzinga
This AutoZone Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Solid Biosciences (SLDB) Receives Buy Rating Amid Competitive Ad - GuruFocus
SLDB Receives "Buy" Rating from Needham with $16 Target Price | SLDB Stock News - GuruFocus
How Solid Biosciences Inc. stock performs in rising dollar environment2025 Breakouts & Breakdowns & Safe Capital Allocation Plans - Newser
Solid Biosciences’ SGT-212 gains FDA rare paediatric disease status - Yahoo
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Solid Biosciences (Nasdaq: SLDB) issues 23,284 RSUs under 2024 inducement plan - Stock Titan
Solid Biosciences' SGT-212 Receives Rare Pediatric Disease Designation to Treat Friedreich's Ataxia - marketscreener.com
Solid Biosciences receives FDA rare pediatric disease designation for SGT-212 dual route of administration gene therapy - marketscreener.com
Solid Biosciences (SLDB) Gains Key FDA Designation for Gene Ther - GuruFocus
Solid Biosciences Receives FDA Rare Pediatric Disease and Fast Track Designations for SGT-212, a Novel Gene Therapy for Friedreich’s Ataxia - Quiver Quantitative
Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia - The Manila Times
Solid Biosciences Receives FDA Rare Pediatric Disease - GlobeNewswire
Franklin Resources Inc. Has $7.79 Million Position in Solid Biosciences Inc. $SLDB - MarketBeat
Is Solid Biosciences Inc. stock a bargain at current levels2025 Volatility Report & AI Enhanced Trading Alerts - moha.gov.vn
UBS Reaffirms Their Buy Rating on Credit Agricole (0HAI) - The Globe and Mail
SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia - MSN
Solid Biosciences (SLDB) Stock Analysis Report | Financials & Insights - Benzinga
Can Kennametal India Limited Deliver Relative Outperformance to SectorDebt-to-Equity Ratio Analysis & Access Free Tools and Start Investing - earlytimes.in
Is Solid Biosciences Inc a good long term investmentTake Profit Strategies & Free Discover Dynamic Stocks - earlytimes.in
Using Bollinger Bands to evaluate Solid Biosciences Inc.July 2025 Catalysts & Fast Gaining Stock Strategy Reports - newser.com
Why Solid Biosciences Inc. stock is trending among retail tradersJuly 2025 Opening Moves & Reliable Price Action Trade Plans - newser.com
How to forecast Solid Biosciences Inc. trends using time seriesGap Up & Weekly Market Pulse Updates - newser.com
What insider trading reveals about Solid Biosciences Inc. stockJuly 2025 Trends & Intraday High Probability Alerts - newser.com
Candlestick signals on Solid Biosciences Inc. stock todayMarket Sentiment Report & Long-Term Safe Investment Plans - newser.com
Strategies to average down on Solid Biosciences Inc.Watch List & Daily Stock Trend Watchlist - newser.com
What MACD signals say about Solid Biosciences Inc.July 2025 Recap & Reliable Entry Point Trade Alerts - newser.com
Is Solid Biosciences Inc. stock positioned for long term growth - newser.com
Solid Biosciences licenses next-generation AAV capsid to Andelyn By Investing.com - Investing.com Nigeria
Solid Biosciences stock rises after licensing next-generation capsid By Investing.com - Investing.com Nigeria
Solid Biosciences stock rises after licensing next-generation capsid - Investing.com
Solid Biosciences Grants Capsid AAV-SLB101 License to Andelyn Biosciences - MarketScreener
Andelyn Biosciences Signs Licensing Agreement with Solid Biosciences - Contract Pharma
Solid Biosciences (SLDB) Partners with Andelyn Biosciences for G - GuruFocus
Solid Biosciences licenses next-generation AAV capsid to Andelyn - Investing.com
Solid Biosciences Inc Stock (SLDB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Solid Biosciences Inc Stock (SLDB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cumbo Alexander | President and CEO |
Dec 03 '25 |
Sale |
5.11 |
10,808 |
55,229 |
81,388 |
| Hanrahan Jessie | Chief Regulatory Officer |
Dec 03 '25 |
Sale |
5.11 |
4,483 |
22,908 |
26,660 |
| Herzich Paul | Chief Technology Officer |
Dec 03 '25 |
Sale |
5.11 |
2,701 |
13,802 |
26,622 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):